Stock Fundamentals

AI Research Report

Generate a comprehensive financial analysis report powered by AI

PVLA.US Logo

PVLA.US - Current Price

$100.49

Company Information

▼
Company Name
Palvella Therapeutics, Inc
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
ISIN: US6979471090
CIK: 0001742961
Currency: USD
Full Time Employees: 14
Phone: 484 253 1461
Website: https://palvellatx.com
Fiscal Year End: December
IPO Date: Dec 16, 2024
Description:

Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product candidate is QTORIN 3.9% rapamycin anhydrous gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treatment of other mTOR-driven skin diseases. The company is based in Wayne, Pennsylvania

Address:

125 Strafford Avenue, Wayne, PA, United States, 19087

Directors & Officers

▼
Name Title Year Born
Mr. Wesley H. Kaupinen Founder, President, CEO & Director NA
Ms. Kathleen Goin Chief Operating Officer 1971
Dr. Jeffrey Martini Ph.D. Chief Scientific Officer 1978
Mr. Matthew E. Korenberg CFO & Treasurer 1975
Ms. Bohan Wei Vice President of Corporate Development & New Product Planning NA
Ms. Emily Cook Senior Vice President of Clinical Operations NA
Mr. Jason Burdette SVP of CMC & Technical Operations NA
Ms. Ashley Kline Chief Commercial Officer NA
Dr. David W. Osborne Ph.D. Chief Innovation Officer 1961
Dr. Vimal Patel Pharm.D. Senior VP of Medical Affairs NA

Shares Statistics

▼
Shares Outstanding: 11.84M
Shares Float: 6.59M
% Insiders: 2,135.70%
% Institutions: 7,611.20%
Short % Float: 13.46%

Valuation Metrics

▼
Enterprise Value: $1.13B
Trailing P/E: 0.00
Forward P/E: 0.00

Financial Highlights

▼
Market Cap: $1.19B
Book Value: $3.49
Earnings/Share: $-2.92
Profit Margin: 0.00%
Operating Margin: 0.00%
ROA (TTM): -47.54%
ROE (TTM): -301.19%
Revenue (TTM): $0.00
Revenue/Share (TTM): $0.00
Earnings Growth (YOY): 0.00%
Revenue Growth (YOY): 0.00%

Stock Price History

▼

1 Year Price History

2 Years Price History

5 Years Price History

10 Years Price History

Financial Charts

▼

Revenue & Net Income

Operating Expenses

Balance Sheet Overview

Earnings Per Share (EPS)

Earnings History

▼
Date EPS Actual EPS Estimate Difference Surprise %
Sep 30, 2025 -1.03 -2.13 N/A 5,164.32%
Jun 30, 2025 -0.86 -2.03 N/A 5,763.55%
Mar 31, 2025 -0.74 -0.86 N/A 1,395.35%
Dec 31, 2024 -5.37 -0.60 N/A -79,874.48%
Sep 30, 2024 -2.19 N/A N/A N/A
Jun 30, 2024 -2.76 -0.03 N/A -911,233.33%
Mar 31, 2024 -3.95 -0.06 N/A -649,116.67%
Dec 31, 2023 -3.71 -0.12 N/A -298,891.67%
Sep 30, 2023 -8.70 -0.11 N/A -781,045.45%
Jun 30, 2023 4.00 -0.16 N/A 265,264.84%
Mar 31, 2023 -14.40 -0.18 N/A -774,741.14%
Dec 31, 2022 -8.80 -0.23 N/A -372,608.70%
Sep 30, 2022 -10.40 -0.16 N/A -640,000.00%
Jun 30, 2022 -11.20 -0.11 N/A -1,008,181.82%
Mar 31, 2022 -5.60 -0.12 N/A -476,956.52%
Dec 31, 2021 -12.00 -0.14 N/A -878,888.89%
Sep 30, 2021 -19.20 -0.24 N/A -779,149.20%
Jun 30, 2021 -20.00 -0.22 N/A -899,090.91%
Mar 31, 2021 -5.60 -0.17 N/A -319,411.76%
Dec 31, 2020 -20.80 -0.23 N/A -884,623.66%
Sep 30, 2020 -20.80 -0.13 N/A -1,590,000.00%
Jun 30, 2020 -7.20 -0.17 N/A -413,529.41%
Mar 31, 2020 -5.60 -0.17 N/A -319,411.76%
Dec 31, 2019 -4.80 -0.28 N/A -161,428.57%
Sep 30, 2019 -4.00 -0.17 N/A -225,294.12%
Jun 30, 2019 -19.20 -0.22 N/A -862,727.27%
Mar 31, 2019 -16.00 -0.20 N/A -790,000.00%
Dec 31, 2018 -17.60 -0.18 N/A -967,777.78%
Sep 30, 2018 -8.80 -0.12 N/A -723,333.33%
Jun 30, 2018 -0.30 -0.01 N/A -290,800.00%
Mar 31, 2018 -0.17 -0.02 N/A -75,000.00%
Dec 31, 2017 14.40 -0.07 N/A 2,067,142.86%
Sep 30, 2017 -12.72 N/A N/A N/A
Jun 30, 2017 -18.59 N/A N/A N/A
Mar 31, 2017 -14.85 N/A N/A N/A
Dec 31, 2016 -12.19 N/A N/A N/A
Sep 30, 2016 -11.51 N/A N/A N/A
Jun 30, 2016 -11.52 N/A N/A N/A
Mar 31, 2016 -8.36 N/A N/A N/A
Dec 31, 2015 -5.83 N/A N/A N/A
Sep 30, 2015 -8.07 N/A N/A N/A
Jun 30, 2015 -9.60 N/A N/A N/A
Mar 31, 2015 -7.32 N/A N/A N/A
Dec 31, 2014 -11.38 N/A N/A N/A

Balance Sheet (Yearly)

▼
Date Cash Total Debt Total Assets Total Liabilities Total Equity
2024-12-31 $83.60M $N/A $88.23M $25.63M $62.61M
2023-12-31 $7.35M $N/A $7.55M $11.43M $-3.88M
2022-12-31 $16.05M $N/A $16.52M $39.70M $-23.17M
2021-12-31 $117.76M $N/A $153.56M $102.81M $50.76M
2020-12-31 $70.44M $N/A $105.01M $73.98M $31.03M
2019-12-31 $N/A $N/A $N/A $N/A $N/A
2018-12-31 $N/A $N/A $N/A $N/A $N/A
2017-12-31 $N/A $N/A $N/A $N/A $N/A
2016-12-31 $N/A $N/A $N/A $N/A $N/A
2015-12-31 $N/A $N/A $N/A $N/A $N/A
2014-12-31 $N/A $N/A $N/A $N/A $N/A
2013-12-31 $N/A $N/A $N/A $N/A $N/A

Insider Trading

Date Insider Name Title Transaction Type Shares Price Value
Apr 09, 2025 N/A N/A N/A N/A N/A N/A
Dec 18, 2024 N/A N/A N/A N/A N/A N/A

Watchlist

0

No stocks in watchlist